Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Roflumilast on Markers of Bone Metabolism and Endothelial Function in COPD

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2016 by University of Pittsburgh
Information provided by (Responsible Party):
Jessica Bon, University of Pittsburgh Identifier:
First received: December 6, 2012
Last updated: January 5, 2016
Last verified: January 2016
Our primary hypothesis is that Roflumilast (500 μcg, once daily) will significantly decrease surrogate markers of bone metabolism and early cardiovascular disease in individuals with moderate to severe airflow obstruction and a chronic bronchitis phenotype.

Condition Intervention Phase
Chronic Obstructive Pulmonary Disease
Drug: Roflumilast
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effect of Roflumilast on Systemic Markers of Bone Metabolism and Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease

Resource links provided by NLM:

Further study details as provided by University of Pittsburgh:

Primary Outcome Measures:
  • systemic markers of bone metabolism [ Time Frame: 30 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • endothelial function [ Time Frame: 30 days ] [ Designated as safety issue: No ]

Estimated Enrollment: 20
Study Start Date: February 2013
Estimated Study Completion Date: March 2016
Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Study Drug
Roflumilast 500 μcg, once daily, for 30 days
Drug: Roflumilast


Ages Eligible for Study:   50 Years to 70 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects between the ages of 50 and 70 with a minimum of ten-pack years of tobacco exposure, airflow obstruction (FEV1/FVC < 0.70) with an FEV1 < 70%
  • baseline sputum production at least some of the time as reported on the Saint George's Respiratory Questionnaire, and at least one exacerbation within the past year

Exclusion Criteria:

  • Subjects with chronic prednisone use, antiresorptive therapy use (bisphosphonates, calcitonin, parathyroid hormone)
  • Subjects with a body mass index less than 18 or greater than 34
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01745848

Contact: Joseph Mastalski 412-683-7692

United States, Pennsylvania
Emphysema COPD Research Center Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Joseph Mastalski         
Sponsors and Collaborators
University of Pittsburgh
  More Information

Responsible Party: Jessica Bon, Assistant Professor of Medicine, University of Pittsburgh Identifier: NCT01745848     History of Changes
Other Study ID Numbers: PRO12060615 
Study First Received: December 6, 2012
Last Updated: January 5, 2016
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Pittsburgh:

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases processed this record on September 23, 2016